Optimal working dilution should be determined by the investigator.
Restrictions
For Research Use only
Format
Liquid
Concentration
1.0 mg/mL
Loberg, Day, Dunn, Kalikin, Pienta: "Inhibition of decay-accelerating factor (CD55) attenuates prostate cancer growth and survival in vivo." in: Neoplasia (New York, N.Y.), Vol. 8, Issue 1, pp. 69-78, (2006) (PubMed).
Liszewski, Leung, Schraml, Goodship, Atkinson: "Modeling how CD46 deficiency predisposes to atypical hemolytic uremic syndrome." in: Molecular immunology, Vol. 44, Issue 7, pp. 1559-68, (2006) (PubMed).